Christopher Dowson1, Nathan Simpson1, Laura Duffy1, Steven O'Reilly2. 1. Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Ellison Building, Newcastle Upon Tyne, NE2 8ST, UK. 2. Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Ellison Building, Newcastle Upon Tyne, NE2 8ST, UK. steven.oreilly@northumbria.ac.uk.
Abstract
PURPOSE OF REVIEW: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease which has defined three hallmarks: Small vessel vasculopathy, production of autoantibodies and fibroblast dysfunction. The exact aetiology of the disease remains unknown, due to the complex nature of the cellular signalling pathways involved. However, there is strong and consistent evidence that the innate system, in particular toll-like receptor signalling, is contributing to the progression and perhaps onset of systemic sclerosis. In light of this evidence, this review examines the role of innate immunity in systemic sclerosis and where appropriate suggests avenues for therapeutic modulation in SSc. RECENT FINDINGS: Multiple lines of evidence suggest that Toll-like receptors (TLRs) are dysregulated and emerging evidence suggests that many endogenous ligands are also elevated in the disease leading to 'sterile inflammation' and ultimately the induction of fibrosis. Currently, no effective therapy exists and exploiting the innate immune system perturbation may be one possible avenue. Innate immune dysregulation is key in SSc pathogenesis and may represent a novel target.
PURPOSE OF REVIEW: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease which has defined three hallmarks: Small vessel vasculopathy, production of autoantibodies and fibroblast dysfunction. The exact aetiology of the disease remains unknown, due to the complex nature of the cellular signalling pathways involved. However, there is strong and consistent evidence that the innate system, in particular toll-like receptor signalling, is contributing to the progression and perhaps onset of systemic sclerosis. In light of this evidence, this review examines the role of innate immunity in systemic sclerosis and where appropriate suggests avenues for therapeutic modulation in SSc. RECENT FINDINGS: Multiple lines of evidence suggest that Toll-like receptors (TLRs) are dysregulated and emerging evidence suggests that many endogenous ligands are also elevated in the disease leading to 'sterile inflammation' and ultimately the induction of fibrosis. Currently, no effective therapy exists and exploiting the innate immune system perturbation may be one possible avenue. Innate immune dysregulation is key in SSc pathogenesis and may represent a novel target.
Authors: Eguzkine Ochoa; José-Ezequiel Martin; Shervin Assasi; Lorenzo Beretta; Patricia Carreira; Alfredo Guillén; Carmen Pilar Simeón; Eugénie Koumakis; Philippe Dieude; Yannick Allanore; Francisco J García-Hernández; Gerard Espinosa; Ivan Castellví; Jose Luis Trapiella; Luis Rodriguez; Miguel Ángel González-Gay; María Victoria Egurbide; Luis Sáez; Jose Luis Callejas-Rubio; Jose Antonio Vargas-Hitos; Nicolas Hunzelmann; Gabriela Riemekasten; Torsten Witte; Jörg H W Distler; Alexander Kreuter; Claudio Lunardi; Alessandro Santaniello; Filemon K Tan; Paul G Shiels; Ariane Herrick; Jane Worthington; Madelon C Vonk; Bobby P Koeleman; Timothy R D J Radstake; Maureen D Mayes; Javier Martin Journal: Clin Exp Rheumatol Date: 2015-08-27 Impact factor: 4.473
Authors: O Distler; T Pap; O Kowal-Bielecka; R Meyringer; S Guiducci; M Landthaler; J Schölmerich; B A Michel; R E Gay; M Matucci-Cerinic; S Gay; U Müller-Ladner Journal: Arthritis Rheum Date: 2001-11
Authors: Gökhan M Mutlu; G R Scott Budinger; Minghua Wu; Anna P Lam; Aaron Zirk; Stephanie Rivera; Daniela Urich; Sergio E Chiarella; Leonard H T Go; Asish K Ghosh; Moises Selman; Annie Pardo; John Varga; David W Kamp; Navdeep S Chandel; Jacob Iasha Sznajder; Manu Jain Journal: Thorax Date: 2011-09-15 Impact factor: 9.139
Authors: Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis Journal: Arthritis Rheum Date: 2011-11
Authors: K A Patterson; P J Roberts-Thomson; S Lester; J A Tan; P Hakendorf; M Rischmueller; J Zochling; J Sahhar; P Nash; J Roddy; C Hill; M Nikpour; W Stevens; S M Proudman; J G Walker Journal: Arthritis Rheumatol Date: 2015-12 Impact factor: 10.995
Authors: Rudolf Mierau; Pia Moinzadeh; Gabriela Riemekasten; Inga Melchers; Michael Meurer; Frank Reichenberger; Michael Buslau; Margitta Worm; Norbert Blank; Rüdiger Hein; Ulf Müller-Ladner; Annegret Kuhn; Cord Sunderkötter; Aaron Juche; Christiane Pfeiffer; Christoph Fiehn; Michael Sticherling; Percy Lehmann; Rudolf Stadler; Eckhard Schulze-Lohoff; Cornelia Seitz; Ivan Foeldvari; Thomas Krieg; Ekkehard Genth; Nicolas Hunzelmann Journal: Arthritis Res Ther Date: 2011-10-21 Impact factor: 5.156
Authors: José Manuel López-Cacho; Soledad Gallardo; Manuel Posada; Miriam Aguerri; David Calzada; Teodoro Mayayo; María Luisa González-Rodríguez; Antonio María Rabasco; Carlos Lahoz; Blanca Cárdaba Journal: Biomed Res Int Date: 2014-04-10 Impact factor: 3.411
Authors: Ryan T Kendall; Ludivine Renaud; John E Baatz; Maya Malaab; Xinh-Xinh Nguyen; Carol A Feghali-Bostwick Journal: J Proteomics Date: 2021-04-27 Impact factor: 3.855
Authors: P Cipriani; R Giacomelli; P Di Benedetto; P Ruscitti; O Berardicurti; M Vomero; L Navarini; V Dolo Journal: Clin Exp Immunol Date: 2021-04-18 Impact factor: 5.732